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Trypanosoma cruzi in the face of climate change:
current and future directions for treatment and research

Zoe Kellermyer
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December 8, 2021

The challenges present in the face of climate change are vast, and new ones are
constantly coming to recognition. Alterations of precipitation patterns are increasing droughts
along the equator and lowering crop yield. Warming temperatures are melting glaciers and ice
caps, leading to rising sea levels and the subsequent destruction of communities living along the
coast across the world. Additionally, the behaviors that began these changes are also the ones
perpetuating them. Population growth has led to the constant move further into natural areas,
cutting down forests and destroying ecosystems. The continued use of fossil fuels has led to the
destruction of the ozone layer, which further alters the global climate and thus perpetuates the
cycle as further resources are used to protect ourselves from these changes.
While much of the focus of the severe effects of climate change is focused on the
prevalence of natural disasters and climbing temperatures, there is an important consequence of
climate change that is less often discussed – the projected increase in vector-borne diseases,
especially those caused by parasites. The elongated and increasingly intense warm seasons in
regions north and south of the equator have led to the decline of colder ones, which serve an
important purpose in vector-borne parasitic disease management. Additionally, changes in
precipitation patterns have affected the life span and cycle of many insect vectors. This is leading
to the increase in parasitic diseases in countries that have previously had few cases as well as the
increased intensity of disease in areas where it is already prevalent.
Trypanosoma cruzi, the protozoan parasite and causative agent of Chagas disease, is
predicted to have both of these aforementioned effects on disease prevalence. It has detrimental
effects on the individual and the society, with current estimates placing between six and seven
million individuals infected worldwide.1 As of 2013, the global annual burden of Chagas disease
was around 806,170 disability-adjusted life years (DALYS) and $627.46 million in health-care
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costs – however, these numbers do not include the cost and DALYS associated with the chronic
heart disease that can arise years later.2 While T. cruzi is endemic in many areas of Latin
America, the many effects of climate change – including changes in precipitation patterns,
increased temperatures, and migration – are causing projected increases in the vector range,
putting many more at risk of becoming infected with the parasite. Thus, with limited treatment
options for T. cruzi, it is important to increase awareness and the need for further research into
the parasite and how to effectively prevent and treat it. Here, the projected impacts of vector
range in the Western hemisphere due to climate change are reviewed, along with an evaluation of
the current treatments. In addition, recommendations for areas of further research for prevention
and new treatments are proposed.

Overview of T. cruzi
T. cruzi is one of the major species of trypanosomes that cause disease in humans. In
Africa, Trypanosoma brucei is the causative agent of sleeping sickness whereas T. cruzi causes
Chagas disease primarily in the Americas.3 Chagas Disease is common in certain areas in
Mexico, Central America, and South America, where the majority of cases are concentrated.1
While humans are the intermediate host for T. cruzi, many other organisms can harbor the
parasite, including armadillos, raccoons, opossums, woodrats, and domestic dogs. T. cruzi is
transmitted by the definitive host, the kissing bug, which include different genera and species of
triatomines within the family Reduviidae.3 When the kissing bug takes a blood meal from the
human host, it gets so full that it defecates, passing the metacyclic form of the trypomastigotes
onto the skin in the process. This bite is itchy, causing the host to scratch the area and in doing
so, inadvertently rub the parasite into the wound or, more commonly, into the eye as the bite is
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typically on the face. This metacyclic trypomastigote is the infective form for humans, and, when
it enters the body, is met by a variety of host immune molecules and cells. It gets coated with
molecules (called complement) and is subsequently engulfed by a macrophage or other
phagocytic immune cell at the site of infection. Inside this cell, T. cruzi undergoes further
development, differentiating into its amastigote stage. The amastigotes multiply quickly before
further differentiating into the bloodstream trypomastigote stage. Both phases will emerge from
the cell and enter the blood, where they can circulate and infect other tissues throughout the
body. This bloodstream trypomastigote stage is also the infective stage for the kissing bug and
when it takes a blood meal from an infected host – be it human or one of the aforementioned
mammals – ingests the parasite as well, which travel to the triatomine’s midgut and further
differentiate into epimastigotes. These migrate to the hindgut where they continue to differentiate
into metacyclic trypomastigotes and can be passed to a new host.3
While this vector is a common mechanism of transmission, T. cruzi can also be passed
through blood transfusions, organ transplants, and transplacental from mother to fetus.3 If it is
transmitted via a triatomine vector, however, the host typically experiences initial swelling at the
site of infection, commonly the eye or the area in which the bite occurred. In this acute stage,
there are high levels of the bloodstream trypomastigote as they travel throughout the body, and
the host may also experience a mild fever, body aches, nausea, vomiting, and diarrhea.3 In the
chronic stage, many individuals are asymptomatic, but around 30% experience difficulties
swallowing food, passing stool, and heart-related problems as the parasite commonly settles in
the esophagus, colon, and heart around 10 to 30 years after the initial infection. This stage is
characterized by low levels of the bloodstream trypomastigote as the tissue amastigote is the
predominant stage, raising a chronic immune response that leads to the inflammation and
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scarring seen in these organs.4 Ultimately, this can lead to severe manifestations of the chronic
infection, such as heart failure and death.

Climate Change and Vector Range
The primary climate forces that influence insect vector range is increasing temperatures,
both in its duration and intensity, and more rainfall during the dry seasons. This is especially
important for the kissing bugs, as in North and South America, the range for vector-transmitted
Chagas disease is currently as far north as the southern United States and as far south as
Argentina and Chile.1,5 This range is projected to continue this northern and southern expansion
as climate change progresses, which not only has implications for vector-transmitted Chagas
disease, but non-vector forms as well due to the increase and perpetuation of human cases due to
migration.
On the southern end of this range in Chile, the main kissing bug species that can transmit
T. cruzi are Triatoma infestans, Mepraia gajardoi, and Mepraia spinolai, each of which have
slightly different projected geological distributions.6,7 Results from a 2018 study on the change in
T. infestans distribution under different climate scenarios found that the distribution of both the
vector and Chagas’ disease cases are linked to increased temperatures and rainfall in the drier
months, both factors projected in changing climate.6 Generally, the likely distributions are
further inland, primarily due to the increased precipitation, as well as further south from the
temperature changes.6,7 However, the climate changes in this region are predicted to also make
some areas where T. cruzi has high prevalence less suitable for the vector’s survival. While this
would greatly benefit those within the area, this likely means that the vector will expand
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outwards into newer territories within the region. If that is the case, then the chances are that the
trypanosome will follow as well.
On the northern edge of the vector range, the mid-to-southern regions of the United
States are becoming increasingly suitable for triatomine species capable of passing T. cruzi, with
the current range of vector-competent kissing bugs reaching up to Pennsylvania. Further south,
however, triatomines currently infected with T. cruzi are increasing in prevalence. In
southeastern Louisiana, for example, a 2007 study of T. sanguisuga found that of the live insects
able to be collected, 61.4% of them carried T. cruzi, which is the highest reported prevalence at
the time of publication.8 A similar study conducted in Arizona found that of the triatomines
collected, 42.5% were infected.9 Out of those insects that were collected from indoor residential
sites, 63% of the homes had a kissing bug that carried T. cruzi.9 Arizona and Louisiana are not
the only states found to have high numbers of infected competent kissing bugs – in a study of
triatomine vectors across 18 southern states, 92.9% of vector-competent collected specimen were
found indoors as well as dog kennels and areas directly adjacent to homes, such as patios and
garages.10 As people are commonly bitten and subsequently infected at night, areas where there
are good housing conditions, such as those with sealable entrances and no cracks where bugs
could enter, typically have a lower prevalence of infection. However, the high number of
infected triatomine bugs found to be present within the homes is cause for concern. Additionally,
as dogs and other animals can act as reservoir hosts for T. cruzi, an area with vector-competent
kissing bugs present could lead to higher cases of Chagas disease through increased vector
transmission.
Although the climate in the northern states is currently less suitable for kissing bugs,
projections of temperature and precipitation shifts are likely to make them a perfectly viable
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habitat. The predicted shift is further north-east, potentially as far north as Michigan and New
York.11 However, there are geographical gaps in this projected move where the habitat is less
suitable for the kissing bugs, and thus their migration will depend largely on human movement.11
This seems as though it will be difficult for there to be a significant risk of Chagas’ disease, but
as the world continues to warm, sea levels will rise and cause the southernmost states to become
less habitable for many. This could lead to increased movement further north and thus the
increased potential for infected kissing bugs to hitch a ride beyond the gap of unsuitable habitat
and to the areas where they can prosper. Additionally, those with chronic, asymptomatic Chagas
disease could relocate to areas where vector-competent triatomines already reside and increase
cases that way. Thus, it is important to have effective treatments available in the likely event that
T. cruzi spreads further north.

Current Treatments and Resistance
Despite Chagas disease having been discovered over a century ago, there are still only
two recognized chemotherapeutic treatments – benznidazole and nifurtimox, with only
benznidazole being approved for use in the United States. Both drugs are the most effective
when administered early during the acute stage of infection, as circulating levels of the
extracellular trypomastigote are highest. Unfortunately, these drugs have shown limited
effectiveness in treatment of the chronic stage of Chagas disease, as the primary life cycle stage
is the latent amastigote.12 The effectiveness that can be seen is primarily in reducing the levels of
the blood-stage trypomastigotes – however, these levels vary from patient to patient due to
factors such as the patient’s immune response. There are cases in which administration of these
anti-parasitic drugs, primarily nifurtimox, have shown effectiveness in slowing the advancement
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of cardiac problems due to T. cruzi, but there is limited data to support it as a long-term solution
to the problem.
While in different drug classes, both benznidazole and nifurtimox work through the
reduction of the nitro group on the compound, creating a reactive compound that can damage the
cell. Reactive species are common byproducts created through metabolism of various substrates,
and in trypanosomes, they are neutralized by the enzyme trypanothione reductase, which is
critical to the survival of the organism. The administration of benznidazole and nifurtimox,
however, create an excess of radical and reactive compounds, thus depleting trypanothione
reductase and eventually breaking down cellular components to the point of cell death.12,13,14 It is
believed that the reactive metabolites formed cause damage primarily to the DNA, although it is
not confirmed that this damage is what leads to the parasite death.12 While both drugs are
believed to act similarly, benznidazole is currently the front-line medication used to treat acute
Chagas disease due to its lower toxicity to the patient.
Studies have been done in order to determine the underlying causes of resistance, which
is a difficult feat as the ways in which the drugs work are still unconfirmed. While the basis for
resistance has remained understudied, one of the key intracellular enzymes that has been
implicated is the mitochondrial type 1 nitroreductase TcNTR-1, which activates both drugs and
forms the reactive metabolites believed to cause DNA damage and subsequent cell death.
Previous studies have noted that reduced expression of the TcNTR-1 gene lowers responsiveness
to treatment by benznidazole, with up to a fourfold decrease in effectiveness.15,16 Additionally,
resistance was easily inducible without impact to TcNTR-1 function, and both of these finding
suggest that there are other processes that T. cruzi can use to handle the introduction of the
drug.15,16
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Due to the mechanism through which benznidazole and nifurtimox are believed to work,
the link between resistance and decreased TcNTR-1 expression suggests that there are other
enzymes that activate benznidazole in a way that toxic metabolites aren’t formed, as well as the
likelihood that other enzymes are present that can neutralize those metabolites if they are formed.
There also may be additional efflux mechanisms that allow the parasite to more readily send the
foreign substrate out.15,16 Multidrug resistance (MDR), or broad-spectrum resistance to
antiparasitic drugs, has been linked with overexpression of proteins within the ATP-binding
cassette (ABC) family, which are membrane transporters involved in multiple processes
including efflux.17 ABC proteins are common in both eukaryotes and prokaryotes and have been
implicated in MDR seen in a variety of diseases. In T. cruzi, multiple proteins in this family have
been associated with the MDR phenotype, including the P-glycoprotein, although results are not
consistent regarding its involvement.17,18
In addition to decreasing efficacy, the drugs for treating T. cruzi come with many side
effects. Nifurtimox is currently the second choice for treatment as it has been seen to cause more
adverse effects (AE) than benznidazole, although there hasn’t been much research into these
effects. This is partially due to overall lack of research into the drug, leading to challenges in
administering the proper dosage and subsequent AEs varying in their severity. A 2010 study
performed in Geneva, Switzerland of Latin American migrants with Chagas disease was
performed to investigate the connection between dosage of nifurtimox and AEs experienced by
the patients, who were given 10mg/kg per day for 60 days.19 The results showed that just over
half of the patients in the study were able to complete the entire course of treatment with over a
quarter of participants unable to tolerate it for more than 30 days.19 The most common and
expected AEs seen were digestive and neurological, and despite the majority being mild to
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moderate in severity, multiple AEs were often experienced concurrently.19 Participants who had
unexpected, but relatively mild AE’s – such as fever and temporary short-term memory loss –
had their dosage reduced or stopped completely, while those with severe and unexpected AEs –
including inflammation of the heart tissue and severe systemic drug reactions – either
temporarily or completely ended their treatment.19
These effects, as well as the number of participants who had to suspend or end treatment,
is seen in similar studies evaluating nifurtimox as well as benznidazole. Compared side by side,
benznidazole has shown to be more effective and less toxic, resulting in fewer patients needing
to discontinue treatment.20,21 As these studies were conducted from the late 1990s to 2010, it is
likely that the effects of treatment remain consistent while the efficacy does not. As previously
discussed, T. cruzi can readily mutate and can exhibit MDR, and as resistance is widely seen, the
drugs that continue to be administered are remaining just as toxic while becoming less effective.
This also raises the problem of the continued spread of T. cruzi during treatment with
benznidazole or nifurtimox. If an infected individual needs to pause treatment due to
experiencing a range of AEs, this allows for advancement of Chagas disease and increased
amastigotes settling in tissues. Additionally, it was seen that AEs are typically seen early in
treatment, and thus if treatment is halted, there are likely still enough bloodstream
trypomastigotes that can be taken up by kissing bugs during a blood meal.19 This can also
perpetuate drug resistance, as the parasites remaining in the patient after treatment, whether
completed or not, are likely the ones that are resistant to it. Thus, the use of benznidazole and
nifurtimox as well as the lack of research into new treatments has a variety of effects, from those
experienced by the individual as well as the potential for further transmission.
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The continued use of these two approved drugs drives evolution in T. cruzi, as it creates
high evolutionary pressure and selection for the parasites that have alternative processes for
dealing with the administered treatment, whether that is through increased efflux, alternative
activation methods, or other mechanisms. However, there are other reasons underlying the need
for new therapies, such as the high rate of discontinuation of treatment. With the additional
factor of climate change predicted to further enhancing habitats suitable for vectors, the prospect
of increased transmission with resistant parasites and poorly tolerated, limited drug treatments, it
is imperative that new therapies are investigated.

New Drug Targets
One of the main similarities with T. cruzi and fungi is ergosterol biosynthesis, which has
made this pathway one of interest for further research as a treatment targeting it is likely to have
fewer AEs experienced by the human host. There are a few ergosterol inhibitors that have been
in clinical trials, one highly effective one being Posaconazole. While it has been shown to have a
curative effect on both acute and chronic phases of Chagas disease, it is costly and highly
complex to produce.22 Thus, it is a less attractive therapeutic option despite its high efficacy –
nonetheless, it is important to continue to pursue this drug as it is beneficial to have a variety of
treatment options available.
Another promising ergosterol biosynthesis inhibitors that is currently in clinical trials is
E1224, a prodrug that has shown to have anti-T. cruzi activity. Prodrugs are inactive compounds
that turn into a better absorbing, biologically active drug after metabolism by the host enzymes –
E1224, in particular, is a prodrug of a discontinued antifungal called ravuconazole.23 In phase II
of clinical trials, E1224 was shown to have a slower and more short-term effect on clearing the
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parasite – however, when combined with benznidazole and administered in mouse models, it was
shown to have a 100% cure rate against a multidrug-resistant strain of T. cruzi.22,23 This
combination therapy has also been shown to have no clinically significant drug interactions as
well as fewer and more benign AEs experienced due to the lower levels of both drugs needing to
be administered, making this a prime candidate for human treatment.23 Since ergosterol is an
important membrane component of both the trypomastigote and amastigote life stages, these
drugs are likely to be important in their ability to treat the chronic phase and decreasing the
burden caused by the advanced disease.
While not currently in trials, targeting trypanothione reductase enzymes in T. cruzi are a
potentially useful target. As previously mentioned, trypanothione reductase is a key enzyme
involved in relieving oxidative stress within the parasite. Thus far, it has not been one of the
enzymes implicated in resistance, but it is critical to the survival of the organism. By inhibiting
the parasite’s ability to neutralize naturally created reactive species, there would be a decreased
need for treatments such as benznidazole and nifurtimox, whose products are toxic to the host as
well as the parasite. Despite this information being known known for over 20 years, no
successful inhibitors of this enzyme have been created. Trypanothione inhibitors could
theoretically act as a monotherapy but would likely be used most effectively as a component of a
combination therapy – regardless, it could prove to be a promising drug target.
Targeting intracellular metabolic processes may also prove to be a viable treatment
option for both the extracellular trypomastigotes and intracellular amastigotes. It has been shown
that amastigote survival and proliferation is highly dependent on the breakdown of long chain
fatty acids found in the host cell through beta-oxidation.24 However, it is not yet known if this is
a similar pathway used in mammals to break down these compounds. Thus, more research is
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needed into the metabolic processes of T. cruzi in order to determine if there are viable pathways
that could be targeted, as inhibitors of unique aspects could be a supplement to alternate
treatments to slow the progression of the infection or eliminate the disease.
The success of these treatments also shows the need for increased research into the T.
cruzi genome, the parasite’s composition, and unique metabolic pathways. By elucidating these
aspects of the trypanosome, it not only allows for a starting place for further drug research, but it
may also allow the adaption of previously existing antifungal drugs to be used either as a
monotherapy or combination therapy that may be available at a lower cost to patients.

Host-Targeted Treatment
Current treatment for T. cruzi has shown to be effective only in the acute stage and those
therapies can cause AEs to the point that treatment needs to be discontinued, furthering the
parasite’s resistance to the administered drugs. For chronic Chagas disease, treatment is limited
to symptom management and attempts to prevent inflammation rather than attack the cause of
the disease. However, this approach may be part of the solution. With treatment of chronic
Chagas disease, there are two primary factors that need to be addressed, one of which being
eliminating trypomastigotes in the blood as they can infect other host cells or another host
entirely via various transmission mechanisms. The other factor is the amastigotes within the
cells, which are involved with the tissue scarring and inflammation that cause the acute
myocarditis, mega-colon, and mega-esophagus often seen in later stages of the chronic phase.
This damage isn’t caused by the amastigotes themselves, but rather the immune response
attempting to handle these pathogens and infected host cells. Thus, a potential intervention for
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both the acute and early stages of chronic Chagas disease – before the advancement of heart
disease – may lie in regulating the host’s immune response.
During acute Chagas disease, it is important to prevent cellular entry by the metacyclic
trypomastigotes in order to prevent proliferation. A mechanism through which T. cruzi has been
shown to enter the host cells is through interaction with various G-protein coupled receptors,
which are integral membrane proteins important in converting environmental signals to
intracellular responses.25 Thus, preventing this interaction through G-protein coupled receptor
inhibitors or antagonists could be an option for limiting infection. Interestingly, cannabinoids
have been shown to inhibit G-protein signaling as well as invasion of heart tissue cells, thus
proving to be a potential option for supplementing treatment of Chagas disease in both the early
and late phases of the acute stage.25
During both stages of Chagas disease, different cytokines are deployed by the immune
system to both resist and control the infection. The CD4 subset of T cells help other immune
cells to better perform their function and are thus involved in both short-term and long-term
management of the infection. Within that subset, Th2 and Th1 CD4 T cells are important in
controlling T. cruzi infection, with the former primarily involved in the acute stage of the disease
due to the high level of blood parasites. Th2 cells act against extracellular parasites by recruiting
other cells to the site of infection, primarily eosinophils, mast cells, and B cells, which can create
IgE antibodies. IgE binds to extracellular T. cruzi and further signals to other immune cells to
destroy it. Th1 cells, on the other hand, fight intracellular pathogens in part through the secretion
of interferon-gamma and are found in high levels in individuals with chronic Chagas disease. A
balance of these cells is important for a successful and maximally beneficial host immune
response to T. cruzi.
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During chronic Chagas disease, as previously mentioned, it is important to target both the
blood-stage trypomastigote as well as the immune response to the non-proliferative amastigotes
in the tissues in order to prevent the spread of T. cruzi to others as well as prevent advancement
of the disease. Regarding host-targeted treatments, regulating the immune response, specifically
the cytokines involved, to the latent tissue amastigotes is key. Interleukin-10 (IL-10), for
example, is an anti-inflammatory cytokine involved in regulating the immune response,
including the Th1 subset of CD4 “helper” T cells and their release of interferon-gamma, a
cytokine with many roles in activating both the innate and adaptive immune response. Recently,
synthetic IL-10 molecules have been successfully created, which has positive implications for
many chronic diseases such as this.26 Due to the high Th1 levels seen in chronic Chagas disease,
IL-10 therapy may prove to be an effective option for regulating the inflammation induced by
this T cell subset and slowing the disease progression of the heart, colon, and esophagus.
However, the immune response and cytokines involved in both the chronic and acute stages of T.
cruzi infection require further investigation, as the roles of IL-10 and interferon-gamma both
have multiple roles in the immune response with some of their effects being more harmful than
beneficial.
Another cytokine implicated in the immune response to T. cruzi is interferon-gamma, is
critical in both the innate and adaptive immune responses as it have multiple functions. In the
initial stages of infection, it is secreted by natural killer cells to recruit and increase macrophage
activity as well as interfere with intracellular replication. They also help to activate T cells
specific for T. cruzi and regulate their differentiation. While interferon-gamma has been
implicated in the host immune response to infection by T. cruzi and investigated for therapeutic
use, increasing the levels in the patient is not necessarily a viable option for treatment. When the
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trypomastigote has been phagocytosed by a macrophage, that cell tries to destroy it by fusing the
T. cruzi containing vacuole with the lysosome, forming the phagolysosome. One of the functions
in interferon-gamma is to aids macrophages in this destruction by increasing the acidification of
the phagolysosome containing the pathogen. While other protozoan parasites, such as those
within the Leishmania genus, prevent the formation of the phagolysosome altogether, T. cruzi
needs this fusion to occur. The highly acidic environment within this vacuole activates a low pHdependent pore protein, which allows the disintegration of the phagolysosome and allows the
trypomastigote to enter the cytoplasm.27 Here, it can differentiate into the amastigote phase and
undergo rapid replication. Thus, while high numbers of the Th1 subset of CD4 T cells are present
in the chronic and acute stages of Chagas disease, immune-related therapies stimulating their
proliferation may not be the most effective in this regard. What is important, rather, is to regulate
the balance of the Th1 and Th2 cells throughout the infection in order to maintain a beneficial
response rather than a harmful one. This balance, along with other important immune regulation,
could be accomplished through altering levels of cytokines. It is therefore important to not only
study T. cruzi further, but the immune responses to both the bloodstream trypomastigote and the
intracellular amastigote.

Vaccines and Vaccine-Linked Therapies
While there are no current vaccines for T. cruzi, increasing research into their
development is important in reducing the spread and progression of the disease. While it would
be an important prevention measure to develop, it could also have potential as a treatment due to
the creation of a T. cruzi-specific response. A vaccine could decrease the likelihood of an acute
T. cruzi infection advancing to Chagas disease through balancing adaptive immune cell
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differentiation and proliferation as well as minimizing inflammatory damage during the chronic
stage. Few surface antigens have been implicated as potential vaccination targets, but a
promising one is the calcium-binding protein Tc24. This is important in regulating the amount of
calcium within the parasite and aids in its invasion of host cells.28 Another important antigen is
Tc-TSA-1, a surface protein within the trans-sialidase family of proteins important in escaping
the notice of the host immune system.29 This protein interacts with host cells, stealing the sialic
acid molecules coating them and using them to hide itself from the immune system.
One effective method of vaccination is through the administration of recombinant protein
vaccines. This type of vaccine is created through the insertion of DNA for certain antigens into
bacterial or yeast cells, through which the pathogen’s antigen is expressed and subsequently
isolated. For Tc-TSA-1, a recombinant variation of the antigen in conjunction with adjuvants, or
compounds that stimulate the immune response, have been shown to reduce the level of T. cruzi
in the bloodstream in infected mice.29 Importantly, Tc-TSA-1 was able to be effectively
synthesized and isolated from E. coli with a 95% purification rate and further, was able to be
refolded with a yield of up to 75%.29 Thus, it is possible to effectively produce these proteins in
high enough levels to be utilized in clinical trials. This antigen would make for an effective
vaccine as, if the stimulated adaptive immune system responds quickly to T. cruzi infection,
neutralizing antibodies may be able to bind these proteins and prevent the parasite’s ability to
hide from the immune system through disguising itself with the host cell-surface molecules. It
has also been suggested that recombinant Tc-TSA-1 combined with the recombinant Tc24 may
prove to be a valuable combination in producing a vaccine, as that would likely further increase
the protection against blood-stage trypomastigotes by diversifying the antibodies produced in
response to an infection.
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While Tc-TSA-1 has been shown to a good option alone as a preventative vaccine, Tc24
has been further investigated as a component of a recombinant vaccine-linked therapy. In this
form of treatment, a low dose of benznidazole is administered first in order to reduce the parasite
burden and followed by the vaccine in order to boost the T. cruzi-specific immune response.28
This has been tested in mice with acute Chagas disease, and was shown to significantly reduce
bloodstream trypomastigotes as well as cardiac inflammation due to invasion of cells when
compared to those who were untreated or treated solely with benznidazole or the Tc24
recombinant vaccine.28 This has positive implications for new treatments associated with low
AEs and lower cost, as both recombinant protein vaccines and lower drug doses are much more
affordable. Additionally, the storage for recombinant protein vaccines is very feasible, requiring
only refrigeration. This makes a vaccine-linked treatment highly promising for communities with
fewer resources available and would help to reduce DALYs by effectively treating the acute
stage as well as preventing progression to the chronic phase.

Viral Therapies
The idea of viral therapies for diseases that are challenging to control or eradicate from
the host originated with the antibiotic crisis as well as the search for alternative cancer
treatments. The basis of both therapies is to use a virus specific for the cells being targeted. With
bacterial infections, a treatment called phage therapy is currently being investigated as an
alternative for treatment of antibiotic-resistant bacterial infections. Bacteriophages, or “phages”,
are viruses that naturally occurring and target specific bacterial cells. Resistance hasn’t been seen
thus far and, since phages and the bacteria they infect have been around since they emerged in
evolutionary history, it is likely to be challenging to create resistance through their widespread

Kellermyer 17

use. Alternatively, in cancer therapies, the genetic material in a deactivated virus is replaced with
that of unique cell-surface markers of cancer cells, allowing the virus specifically to seek out
those mutated cells and spread an infection among them. Unlike chemotherapy, this oncolytic
virotherapy does not suppress the immune system and thus gives the body an opportunity to
regroup and have a stronger response against these cells. In both cases, the viruses are highly
specific for the cells they are targeting, thus minimizing the AEs often seen with chemotherapy,
radiation, and antibiotic use. Therefore, the use of viral therapies for T. cruzi infections would be
highly beneficial due to their selectivity for the pathogen and infected cells as well as low AEs
experienced by the patient.
One way towards the creation of protozoal virotherapy is similar to the basis of phage
therapy – finding viruses that naturally infect T. cruzi. Thus far, little attention has been paid to
the protozoan microbiome, despite it having implications on both the parasite’s vitality and
pathogenicity in the host. While there has been no research into the T. cruzi microbiome
specifically, work has been done to investigate other trypanosomatids. Thus far, only species
from the genera Crithidia and Leptomonas have been studied, which are flagellated protozoan
parasites restricted to insects. These studies have found that the viral diversity within these
parasites is vast and contains novel viruses, such as the previously unknown ostravirus.30 Despite
these being insect-restricted parasites, the findings encourage further research into the
microbiomes of the protozoan parasites of humans, which may have clinical implications as
research progresses. Additionally, this shows that parasites such as T. cruzi can be infected with
viruses of their own. While it remains to be determined whether these viruses help or harm them,
the knowledge of unique viruses to these parasites could prove to be a step towards the ability to
alter them for therapeutic purposes.
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Another path that can be taken is akin to that of oncolytic virotherapy through
engineering viruses that could target T. cruzi trypomastigotes or amastigote-infected cells. One
of the challenges of making drugs and vaccines for prokaryotic parasites are that they are also
eukaryotes, so there are fewer unique targets that allow healthy host cells to remain unharmed.
However, oncolytic virotherapy has been very effective in targeting mutated cancer cells, which
shows promise for protozoan infections including T. cruzi. This would be particularly effective
in treating the blood stage trypomastigote, and thus it is critical to find cell surface antigens that
are unique to the parasite. An option for this could be, for example, in receptors surrounding the
flagellar pocket, which is a morphological trait unique to trypanosomatid protozoa.
It is also important to find viruses and antigens highly unique to T. cruzi to lower the risk
of the virus gaining the ability to infect humans. When the virus is replicating within host cells, it
is prone to errors in the replication of the genetic material. These mutations may have no effect,
decrease pathogenicity, or increase it. There is potential for mutations to arise that could lead to
the virus’s ability to interact with receptors similar to the one it is supposed to, so if a cellsurface receptor resembling that of a human cell is chosen, the chances of this crossover
occurring increase. Thus, it is critical that increasing research is done into the receptors found on
the T. cruzi surface in order to find these potential targets.
Unfortunately, viral therapies for diseases are a relatively new treatment and not widely
used. Additionally, it is expensive, as it requires genetic engineering of the virus, genetic testing
of the cancerous cell or bacterial genome, and research into further development. For protozoan
parasites including T. cruzi, there are even more hurdles as more research is required into the
microbiome of the parasite in order to learn about naturally infective viruses as well as if there
are morphological changes in amastigote-infected cells to determine if there are targets for viral
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binding and entry. Therefore, viral therapies are not presently the best solution for treatment of
Chagas disease and T. cruzi infection. However, this could prove to be a highly efficient longterm solution for the disease. By using viruses, the problem of resistance can be reduced as
genetic testing of resistant strains could elucidate the mutations causing resistance and the
genetic material of the virus could be altered accordingly. Research needs to be invested into the
therapeutic use of viruses as they have potential uses in other protozoan diseases seen across the
world that are likely to be extended due to climate change – for now, though, the focus also
needs to be on learning more about the parasite in order to further the development of in-progress
treatments.

Conclusion
As there are many reservoir organisms for T. cruzi, complete eradication of the parasite is
not feasible. Kissing bugs can continue to feed on animals harboring the parasite and
subsequently pass it to humans. Therefore, it is important to focus on prevention as well as
improved treatments for all phases of Chagas disease as more regions become suitable for vector
transmission. While the best preventative measure is to have properly sealed houses to avoid
being bitten by kissing bugs at night, this is not always feasible in lower-income communities.
Having a low-cost and effective vaccine would be highly beneficial in supporting prevention,
and further research into the recombinant protein vaccines, as well as vaccine-linked therapies,
should be invested in. Researching the host immune response and the cytokines involved is
important as not only would that help treat the acute stage of Chagas disease, but the chronic
stage as well. New drug targets, as well as repurposing older ones such as ravuconazole, are
important areas of further investigation as alternatives to benznidazole and nifurtimox, which are
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becoming increasingly resistant and come with many AEs. Looking ahead, viral therapies show
great promise as they become further developed with potential to be adapted for T. cruzi and its
unique targets. For this to occur, further research is needed into the parasite’s microbiome, as
naturally infective viruses of T. cruzi may aid in the development of a viral therapy for Chagas
disease.
However, there are many factors standing in the way of treating the disease in areas that
need it the most. Some of these proposed options are likely to be more costly in their production
and creation than others. Regardless, investing in parasitology research is important in the face of
climate change. Neglected tropical diseases, such as Chagas disease, must not be overlooked any
longer. Protozoan parasites and their vectors, which have previously been limited in their range,
are projected to continue to expand. Prevalence of disease is thus expected to increase as well. In
a situation in which humanity has been constantly playing catch-up, here is an opportunity in
which we can be a step ahead.
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